DE69218364D1 - Verwendung von 17B-N-Mono-substituierten Carbamoyl-4-aza-5a-androst-1-en-3-onen zur Herstellung von Arzneimitteln zur Verhütung von Prostata Karzinomen - Google Patents

Verwendung von 17B-N-Mono-substituierten Carbamoyl-4-aza-5a-androst-1-en-3-onen zur Herstellung von Arzneimitteln zur Verhütung von Prostata Karzinomen

Info

Publication number
DE69218364D1
DE69218364D1 DE69218364T DE69218364T DE69218364D1 DE 69218364 D1 DE69218364 D1 DE 69218364D1 DE 69218364 T DE69218364 T DE 69218364T DE 69218364 T DE69218364 T DE 69218364T DE 69218364 D1 DE69218364 D1 DE 69218364D1
Authority
DE
Germany
Prior art keywords
androst
aza
medicaments
mono
ones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69218364T
Other languages
English (en)
Other versions
DE69218364T2 (de
Inventor
Glenn J Gormley
Elizabeth Stoner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69218364D1 publication Critical patent/DE69218364D1/de
Publication of DE69218364T2 publication Critical patent/DE69218364T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69218364T 1991-12-17 1992-12-10 Verwendung von 17B-N-Mono-substituierten Carbamoyl-4-aza-5a-androst-1-en-3-onen zur Herstellung von Arzneimitteln zur Verhütung von Prostata Karzinomen Expired - Fee Related DE69218364T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80851091A 1991-12-17 1991-12-17

Publications (2)

Publication Number Publication Date
DE69218364D1 true DE69218364D1 (de) 1997-04-24
DE69218364T2 DE69218364T2 (de) 1997-09-25

Family

ID=25198988

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69218364T Expired - Fee Related DE69218364T2 (de) 1991-12-17 1992-12-10 Verwendung von 17B-N-Mono-substituierten Carbamoyl-4-aza-5a-androst-1-en-3-onen zur Herstellung von Arzneimitteln zur Verhütung von Prostata Karzinomen

Country Status (6)

Country Link
US (2) US6268376B1 (de)
EP (1) EP0547691B1 (de)
JP (1) JP2538489B2 (de)
CA (1) CA2084799C (de)
DE (1) DE69218364T2 (de)
LV (1) LV12067B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084799C (en) 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
EP0547687A1 (de) * 1991-12-18 1993-06-23 Merck & Co. Inc. 17-Beta-substituierte Adamantyl/Norbornanyl Carbamoyl-4-Aza-5-Alpha-Androsta-1-En-3-Onen und Androstan-3-Onen
WO1993023420A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS
CA2174234A1 (en) * 1993-11-04 1995-05-11 Raman K. Bakshi 7-substituted-4-aza-steroid derivatives as 5-alpha- reductase inhibitors
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US6093722A (en) 1997-02-26 2000-07-25 Sankyo Company, Limited Method for treating prostate cancer
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
KR100872722B1 (ko) * 2002-06-28 2008-12-05 주식회사 중외제약 피나스테라이드의 제조방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR830000085B1 (ko) * 1978-04-13 1983-02-08 제임스 에프. 너우톤 5α-환원효소 억제제로서 유용한 4-아자-17-치환-5α-안드로스탄-3-온류의 제조방법
AU527030B2 (en) 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
ZA851426B (en) * 1984-02-27 1986-10-29 Merck & Co Inc 17 beta-n-monosubstituted carbamoyl-4-aza-5 alpha-androst-1-en-3-ones as 5 alpha reductase inhibitors
US5049562A (en) 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
GB8505862D0 (en) 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
US4845104A (en) * 1986-11-20 1989-07-04 Merck & Co., Inc. Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
US5021575A (en) 1989-11-13 1991-06-04 Merck & Co., Inc. Method for introducing a 1,2 double bond into azasteroids
GB9002922D0 (en) 1990-02-09 1990-04-04 Erba Carlo Spa 17 beta-substituted-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation
EP0462662A3 (en) * 1990-06-20 1992-08-19 Merck & Co. Inc. 17beta-n-monosubstituted adamantyl/norbornanyl carbamoyl-4-aza-5alpha-androst-1-en-3-ones and androstan-3-ones
US5300294A (en) 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
IE76452B1 (en) 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
CA2084799C (en) 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
EP0547687A1 (de) 1991-12-18 1993-06-23 Merck & Co. Inc. 17-Beta-substituierte Adamantyl/Norbornanyl Carbamoyl-4-Aza-5-Alpha-Androsta-1-En-3-Onen und Androstan-3-Onen

Also Published As

Publication number Publication date
US6268376B1 (en) 2001-07-31
CA2084799A1 (en) 1993-06-18
US20010049376A1 (en) 2001-12-06
JP2538489B2 (ja) 1996-09-25
LV12067A (lv) 1998-06-20
CA2084799C (en) 2003-01-28
EP0547691B1 (de) 1997-03-19
LV12067B (en) 1998-08-20
EP0547691A1 (de) 1993-06-23
US6432971B2 (en) 2002-08-13
DE69218364T2 (de) 1997-09-25
JPH05255381A (ja) 1993-10-05

Similar Documents

Publication Publication Date Title
DE69214499D1 (de) Herstellung von Olefinen
NO921777D0 (no) Fremgangsmaate for fremstilling av isoparaffiner
DE68922524D1 (de) Herstellung von Bisphenolen.
NO934304L (no) Fremgangsmaate for behandling av fluoralumosilikatglass
DE69433699D1 (de) Bestimmung der Durchgängigkeit der Luftwege
NO923526L (no) Fremgangsmaate for fremstilling av nafta
DE69211425D1 (de) Dampfphasenabscheidung von hydriertem Silsesquioxanharz
DE68928783D1 (de) Zwischenverbindungen zur Herstellung von Fungiziden
FI874671A (fi) Anordning foer foerhindrande av laeckage i tryckledningar.
FI934971A (fi) Anlaeggning foer foerbraenning av spraengaemnen
DE3580607D1 (de) Wesentlich gereinigter inhibitorischer faktor gegen tumorwachstum.
ITMI920569A0 (it) Procedimento per la fabbricazione di tastiere
FI971568A (fi) Menetelmä resistenttien kasvainten hoitamiseksi
DE69209871D1 (de) Herstellung von Olefinpolymeren
DE69210276D1 (de) Herstellung von Alpha-Olefinpolymeren
FI900899A0 (fi) Menetelmä naulalevykattotuolin valmistamiseksi
DE69103109D1 (de) Vorrichtungen zur Herstellung von Rädern mit Schrägverzahnung.
DE69207230D1 (de) Herstellung von Kohlenwasserstoffderivaten
AU6142186A (en) Use of melatonin or related compounds for the treatment of psoriasis
DE69218364D1 (de) Verwendung von 17B-N-Mono-substituierten Carbamoyl-4-aza-5a-androst-1-en-3-onen zur Herstellung von Arzneimitteln zur Verhütung von Prostata Karzinomen
NO890483D0 (no) Framgangsmaate for tilvirkning av formlegemer.
DE69514284D1 (de) Herstellung von Catechol-Estrogen-Derivaten
DE69213862D1 (de) Herstellung von Aluminoxanen
DE68910981D1 (de) Herstellung von Flocken.
DE69213830D1 (de) Herstellung von Pigmenten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee